Bicycle Therapeutics - Publications

Publications

Publications

Presentations

2022

PEGS Europe

11.17.2022

Transferrin Receptor 1-targeting Bicycles: A New Platform for Transcytosis

Boulder Peptide Symposium

11.11.2022

Bicycles for precision guided delivery

SITC

11.10.2022

In-depth characterization of cDC1 ex vivo and in vitro models: development and comparison of conventional dendritic cell culture systems...

SITC

11.10.2022

Transcriptional profiling of Bicycle® tumor-targeted CD137 agonist-treated mouse tumors revealed an early and rapid activation of myeloid cells followed...

SITC

11.10.2022

NKp46 engaging Bicycle NK-TICA® drives tumor targeted cytotoxicity

SITC

11.10.2022

BT7455, a fully synthetic Bicycle tumor-targeted immune cell agonist®, leads to potent EphA2-dependent CD137 agonism and robust anti-tumor efficacy

SITC

11.10.2022

Utility of humanized animal models for in vivo evaluation of NK-TICA®, novel Bicycle® tumor-targeted immune cell agonist® (Bicycle TICA®)...

Festival of Biologics

11.07.2022

BT7480, a novel and fully synthetic Bicycle tumor-targeted immune cell agonist®

ACoP

11.03.2022

The application of PK/PD modelling in the clinical development of BT5528 – a novel toxin delivery platform

AACR

10.26.2022

Development of a CD137 receptor occupancy assay to support the phase I/II study of BT7480, a Bicycle tumor-targeted immune...

AACR

10.26.2022

Establishment of an ex vivo tissue culture platform as a preclinical model to assess the mechanism of action of...

ESCMID

10.11.2022

Anti-Infectives Drug Discovery at Bicycle Therapeutics

ESCMID

10.11.2022

PBP inhibitors discovered using a modified phage display platform (Bicycles)

ESCMID

10.11.2022

Characterisation of novel, non-covalent cyclic peptide (Bicycles®) inhibitors of PBP3s from important Gram-negative

Immuno UK

09.30.2022

Bicycle Therapeutics: Precision-guided immune agonism for the treatment of cancer

CICON

09.29.2022

BT7480, a synthetic Bicycle tumor-targeted immune cell agonist® (Bicycle TICA®), induces reprogramming of the tumor immune microenvironment through tumor...

World Clinical Biomarkers & CDx Summit

09.28.2022

Translating preclinical findings into clinical biomarker assays to support the Phase I/II study of BT7480, a Bicycle tumor-targeted immune...

ASCO

06.06.2022

A Combined Phase I/II Study of a Novel Bicycle Tumor-targeted Immune Cell Agonist® BT7480 in Patients with Nectin-4 Associated Advanced Malignancies

AACR

04.10.2022

BT8009-100 Phase I/II Study of Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with...

AACR

04.08.2022

Modeling the cDC1 ex vivo and in vitro: Development and characterization of a conventional dendritic cell culture system for...

AACR

04.08.2022

Generation of a Bicycle NK-TICA™, a novel NK cell engaging molecule designed to induce targeted tumor cytotoxicity

AACR

04.08.2022

Activity of the erythropoietin-producing hepatocellular A2 receptor (EphA2) targeting Bicycle® Toxin Conjugate (BTC™) BCY6033 in EGFR inhibitor resistant non-small...

AACR

04.08.2022

Development of a CD137 receptor occupancy assay to support the phase I/II study of BT7480, a Bicycle® tumor-targeted immune cell...

Microbiology Society Annual Meeting

04.07.2022

Bicycle®: A novel therapeutic modality for SARS-CoV-2

2021

EuroTIDES

11.19.2021

Bicycles, bi-cyclic peptides, novel small molecule delivery systems for RNA therapeutics

SITC

11.12.2021

Quantitation of CD137 and Nectin-4 expression across multiple tumor types to support indication selection for BT7480, a Bicycle tumor-targeted immune cell...

SITC

11.12.2021

Establishing the preclinical/translational PK/PD relationship for BT7480, a Nectin-4/CD137 Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™)

SITC

11.12.2021

An integrative approach to optimize a synthetic EphA2-dependent CD137 agonist: Balancing potency, physiochemical properties, and pharmacokinetics to achieve robust...

SITC

11.12.2021

Generation of a Bicycle NK-TICA™, a novel NK cell engaging molecule designed to induce targeted tumor cytotoxicity

AACR-NCI-EORTC

10.07.2021

A first in class phase I/II study of the novel bicyclic peptide and MMAE conjugate, BT5528, in patients with...

ASCO

06.04.2021

A Combined Phase I/II Study of BT8009 a Novel Bicycle® Toxin Conjugate with MMAE in Patients with Advanced Malignancies with...

AACR

04.12.2021

BT7480, a novel Nectin-4 dependent agonist of the immune cell costimulatory receptor CD137

AACR

04.12.2021

Integrative surfaceome profiling identifies immunotherapeutic targets in osteosarcoma and preclinical testing of BT1769, an MT1-MMP-targeted Bicycle® toxin conjugate, in...

AACR

04.10.2021

Molecular-based enrichment strategy for Nectin-4 targeted Bicycle toxin conjugate BT8009

AACR

04.10.2021

Nectin-4-dependent immune cell stimulation and anti-tumor efficacy by BT7480, a Nectin-4/CD137 Bicycle® tumor-targeted immune cell agonist (TICA™)

AACR

04.10.2021

Microinjection of Nectin-4/CD137 tumor-targeted immune cell agonist (TICA™) activates the local tumor microenvironment

AACR

04.10.2021

A multi tumor survey of Nectin-4 expression to guide BT8009 indication selection

AACR

04.10.2021

Rapid Accumulation of Cytotoxic Payload in Tumor Tissue Drives BT5528 Activity in Tumor Models

2020

SITC

11.09.2020

EphA2/CD137 Bicycle® tumor-targeted immune cell agonists (TICAs™) induce tumor regressions, immunogenic memory, and reprogramming of the tumor immune microenvironment

SITC

11.09.2020

BT7480, a fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonism and modulation of tumor immune...

AACR Tumor Immunology & Immunotherapy

10.19.2020

BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonism

AACR Tumor Immunology & Immunotherapy

10.19.2020

Development of CD137 (4-1BB) receptor occupancy assay using fluorescently labeled Bicycles®

ESMO

09.17.2020

BT8009-100 Phase I/II Study of the Safety, Pharmacokinetics, & Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing...

AACR

06.22.2020

A survey of EphA2 expression by immunohistochemistry (IHC) in tumor tissue microarrays (TMAs) to support BT5528 indication selection

AACR

06.22.2020

A novel fully synthetic dual targeted EphA2/CD137 Bicycle® peptide induces tumor localized CD137 agonist

AACR

06.22.2020

BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonist

ASCO

05.29.2020

BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies...

2019

SITC

11.09.2019

A novel fully synthetic dual targeted EphA2/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism

SITC

11.09.2019

A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism

SITC

11.06.2019

A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism

AACR-NCI-EORTC

10.29.2019

BT8009, a Bicycle® Toxin Conjugate targeting Nectin-4, shows target selectivity, and efficacy in preclinical large and small tumor models.

AACR-NCI-EORTC

10.29.2019

BT5528, a Bicycle Toxin Conjugate targeting EphA2: mechanism of action and clinical translation

AACR-NCI-EORTC

10.27.2019

MT1-MMP Immunohistochemistry (IHC) analysis of tumor microarrays (TMAs) using a novel scoring system guides patient selection for BT1718 expansion...

World ADC Congress 2019

10.11.2019

BT5528, an EphA2-targeting Bicycle® Toxin Conjugate

ESMO

09.28.2019

Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC),...

30th Symposium on Medicinal Chemistry

05.02.2019

BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): Profound efficacy without bleeding and coagulation abnormalities in animal models

AACR

04.02.2019

BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models

9th Annual World ADC Conferene

03.06.2019

BT5528: A Bicycle Toxin Conjugate Targeting EphA2 for the Treatment of Solid Tumours

2018

EORTC

11.13.2018

Preliminary pharmacokinetic assessment of BT1718: Aphase I/IIatrial of BT1718 (a first in class Bicycle Toxin Conjugate) in patients with advanced...

EORTC

11.13.2018

BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): profound efficacy without bleeding and coagulation abnormalities in animal models

PEGS

11.12.2018

Novel Multimers of Bicyclic Peptides Cluster and Activate CD137 (4-1BB): A Costimulatory T-Cell Checkpoint Receptor

SITC

11.06.2018

Activation of the T cell costimulatory protein CD137 using multivalent bicyclic peptides

ELRIG Drug Discovery

10.09.2018

Novel Bicyclic Peptide Multimers Activate T Cell Costimulatory Protein CD137

ELRIG Drug Discovery

10.09.2018

Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137

NCRI

10.01.2018

A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Toxin Conjugate) given intravenously in...

35th European Peptide Symposium

08.01.2018

Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137

Promega Biologics

07.18.2018

Novel Bicyclic Peptide Multimers Activate T Cell Costimulatory Protein CD137

ASCO

06.05.2018

A Cancer Research UK phase I/IIatrial of BT1718 (a first in class Bicycle Toxin Conjugate) given intravenously in patients with...

AACR

04.14.2018

Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137

AACR

04.14.2018

Bicycle Toxin Conjugates (BTCs) targeting EphA2 for the treatment of solid tumours: Discovery and selection of BT5528

AACR

04.14.2018

BT5528, a Bicycle Toxin Conjugate (BTC) targeting EphA2 has potent anti-tumour activity without bleeding or coagulation abnormalities in animal models

2017

PEGS

04.30.2017

Bicyclic Peptides for Positron Emission Tomography (PET) Imaging of MT1-MMP Expressing tumours

PEGS

04.30.2017

The Bicycle platform: an efficient technology to generate high affinity, high selectivity molecules (Bicycles®) with unique drug like properties...

PEGS

04.30.2017

Discovery and development of BT1718, a novel bicyclic peptide-maytansinoid conjugate targeting MT1-MMP for the treatment of solid tumours: In vitro and in...

PEGS

04.30.2017

BT1718, a novel Bicycle Drug Conjugate® shows potent anti-tumor activity in diverse cell-derived and patient-derived tumor xenograft models

PEGS

04.30.2017

Identification of high affinity, highly selective bicyclic peptides (Bicycles®) to transmembrane proteins using phage display screening on whole cells

AACR

04.01.2017

Development of BT1718, a novel Bicycle Drug Conjugate for the treatment of lung cancer

AACR

04.01.2017

BT1718, a novel bicyclic peptide-maytansinoid conjugate targeting MT1-MMP for the treatment of solid tumours: Design of bicyclic peptide and...

AACR

04.01.2017

Bicyclic Peptides for Positron Emission Tomography (PET) Imaging of MT1-MMP Expressing Tumors

2012

2009

Publications

2022

MDPI

11.18.2022

Antimicrobial and Cell-Penetrating Peptides: Understanding Penetration for the Design of Novel Conjugate Antibiotics

Journal of Medical Chemistry

10.10.2022

Discovery of BT8009: A Nectin‑4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer

Molecular Cancer Therapeutics

09.16.2022

BT8009; a Nectin-4 targeting Bicycle® Toxin Conjugate for treatment of solid tumors.

Bioconjugate Chemistry

08.02.2022

Gold-Mediated Multiple Cysteine Arylation for the Construction of Highly Constrained Bicycle Peptides

Journal of Medicinal Chemistry

07.12.2022

Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology

Molecular Cancer Therapeutics

06.08.2022

Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma

2021

Journal for ImmunoTherapy of Cancer

11.02.2021

BT7480, a Novel Fully Synthetic Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Induces Tumor Localized CD137 Agonism

Journal for ImmunoTherapy of Cancer

01.26.2021

Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist

2020

ACS Infectious Diseases

08.18.2020

An Assay for Periplasm Entry Advances the Development of Chimeric Peptide Antibiotics

Molecular Cancer Therapeutics

05.12.2020

MMAE delivery using the Bicycle toxin conjugate BT5528

Journal of Medicinal Chemistry

03.30.2020

Identification and Optimization of EphA2-Selective Bicycles for Delivery of Cytotoxic Payloads

2019

AACR Journals

02.15.2019

Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors

2018

ADMET

06.06.2018

Application of biomimetic HPLC to estimate lipophilicity, protein and phospholipid binding of potential peptide therapeutics

Journal of Medicinal Chemistry

03.08.2018

Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema

2017

2012

ChemMedChem

07.01.2012

Bicyclic Peptides with Optimized Ring Size Inhibit Human Plasma Kallikrein and its Orthologues While Sparing Paralogous Proteases

2009

Nature Chem Bio

05.31.2009

Publications

2022

Transferrin Receptor 1-targeting Bicycles: A New Platform for Transcytosis

Bicycles for precision guided delivery

In-depth characterization of cDC1 ex vivo and in vitro models: development and comparison of conventional dendritic cell culture systems...

Transcriptional profiling of Bicycle® tumor-targeted CD137 agonist-treated mouse tumors revealed an early and rapid activation of myeloid cells followed...

NKp46 engaging Bicycle NK-TICA® drives tumor targeted cytotoxicity

BT7455, a fully synthetic Bicycle tumor-targeted immune cell agonist®, leads to potent EphA2-dependent CD137 agonism and robust anti-tumor efficacy

Utility of humanized animal models for in vivo evaluation of NK-TICA®, novel Bicycle® tumor-targeted immune cell agonist® (Bicycle TICA®)...

BT7480, a novel and fully synthetic Bicycle tumor-targeted immune cell agonist®

The application of PK/PD modelling in the clinical development of BT5528 – a novel toxin delivery platform

Development of a CD137 receptor occupancy assay to support the phase I/II study of BT7480, a Bicycle tumor-targeted immune...

Establishment of an ex vivo tissue culture platform as a preclinical model to assess the mechanism of action of...

Anti-Infectives Drug Discovery at Bicycle Therapeutics

PBP inhibitors discovered using a modified phage display platform (Bicycles)

Characterisation of novel, non-covalent cyclic peptide (Bicycles®) inhibitors of PBP3s from important Gram-negative

Bicycle Therapeutics: Precision-guided immune agonism for the treatment of cancer

BT7480, a synthetic Bicycle tumor-targeted immune cell agonist® (Bicycle TICA®), induces reprogramming of the tumor immune microenvironment through tumor...

Translating preclinical findings into clinical biomarker assays to support the Phase I/II study of BT7480, a Bicycle tumor-targeted immune...

A Combined Phase I/II Study of a Novel Bicycle Tumor-targeted Immune Cell Agonist® BT7480 in Patients with Nectin-4 Associated Advanced Malignancies

BT8009-100 Phase I/II Study of Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with...

Modeling the cDC1 ex vivo and in vitro: Development and characterization of a conventional dendritic cell culture system for...

Generation of a Bicycle NK-TICA™, a novel NK cell engaging molecule designed to induce targeted tumor cytotoxicity

Activity of the erythropoietin-producing hepatocellular A2 receptor (EphA2) targeting Bicycle® Toxin Conjugate (BTC™) BCY6033 in EGFR inhibitor resistant non-small...

Development of a CD137 receptor occupancy assay to support the phase I/II study of BT7480, a Bicycle® tumor-targeted immune cell...

Bicycle®: A novel therapeutic modality for SARS-CoV-2

2021

Bicycles, bi-cyclic peptides, novel small molecule delivery systems for RNA therapeutics

Quantitation of CD137 and Nectin-4 expression across multiple tumor types to support indication selection for BT7480, a Bicycle tumor-targeted immune cell...

Establishing the preclinical/translational PK/PD relationship for BT7480, a Nectin-4/CD137 Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™)

An integrative approach to optimize a synthetic EphA2-dependent CD137 agonist: Balancing potency, physiochemical properties, and pharmacokinetics to achieve robust...

Generation of a Bicycle NK-TICA™, a novel NK cell engaging molecule designed to induce targeted tumor cytotoxicity

A first in class phase I/II study of the novel bicyclic peptide and MMAE conjugate, BT5528, in patients with...

A Combined Phase I/II Study of BT8009 a Novel Bicycle® Toxin Conjugate with MMAE in Patients with Advanced Malignancies with...

BT7480, a novel Nectin-4 dependent agonist of the immune cell costimulatory receptor CD137

Integrative surfaceome profiling identifies immunotherapeutic targets in osteosarcoma and preclinical testing of BT1769, an MT1-MMP-targeted Bicycle® toxin conjugate, in...

Molecular-based enrichment strategy for Nectin-4 targeted Bicycle toxin conjugate BT8009

Nectin-4-dependent immune cell stimulation and anti-tumor efficacy by BT7480, a Nectin-4/CD137 Bicycle® tumor-targeted immune cell agonist (TICA™)￼

Microinjection of Nectin-4/CD137 tumor-targeted immune cell agonist (TICA™) activates the local tumor microenvironment

A multi tumor survey of Nectin-4 expression to guide BT8009 indication selection

Rapid Accumulation of Cytotoxic Payload in Tumor Tissue Drives BT5528 Activity in Tumor Models

2020

EphA2/CD137 Bicycle® tumor-targeted immune cell agonists (TICAs™) induce tumor regressions, immunogenic memory, and reprogramming of the tumor immune microenvironment

BT7480, a fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonism and modulation of tumor immune...

BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonism

Development of CD137 (4-1BB) receptor occupancy assay using fluorescently labeled Bicycles®

BT8009-100 Phase I/II Study of the Safety, Pharmacokinetics, & Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing...

A survey of EphA2 expression by immunohistochemistry (IHC) in tumor tissue microarrays (TMAs) to support BT5528 indication selection

A novel fully synthetic dual targeted EphA2/CD137 Bicycle® peptide induces tumor localized CD137 agonist

BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonist

BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies...

2019

A novel fully synthetic dual targeted EphA2/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism

A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism

A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism

BT8009, a Bicycle® Toxin Conjugate targeting Nectin-4, shows target selectivity, and efficacy in preclinical large and small tumor models.

BT5528, a Bicycle Toxin Conjugate targeting EphA2: mechanism of action and clinical translation

MT1-MMP Immunohistochemistry (IHC) analysis of tumor microarrays (TMAs) using a novel scoring system guides patient selection for BT1718 expansion...

BT5528, an EphA2-targeting Bicycle® Toxin Conjugate

Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC),...

Bicycles® – An entirely new class of therapeutics

Activation of CD137 using multivalent and tumour targeted bicyclic peptides

Bicycles® – An entirely new class of therapeutics

Activation of 4-1BB using multivalent and tumour targeted bicyclic peptides

BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): Profound efficacy without bleeding and coagulation abnormalities in animal models

BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models

BT5528: A Bicycle Toxin Conjugate Targeting EphA2 for the Treatment of Solid Tumours

2018

Preliminary pharmacokinetic assessment of BT1718: Aphase I/IIatrial of BT1718 (a first in class Bicycle Toxin Conjugate) in patients with advanced...

BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): profound efficacy without bleeding and coagulation abnormalities in animal models

Novel Multimers of Bicyclic Peptides Cluster and Activate CD137 (4-1BB): A Costimulatory T-Cell Checkpoint Receptor

Activation of the T cell costimulatory protein CD137 using multivalent bicyclic peptides

Novel Bicyclic Peptide Multimers Activate T Cell Costimulatory Protein CD137

Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137

A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Toxin Conjugate) given intravenously in...

Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137

Novel Bicyclic Peptide Multimers Activate T Cell Costimulatory Protein CD137

A Cancer Research UK phase I/IIatrial of BT1718 (a first in class Bicycle Toxin Conjugate) given intravenously in patients with...

Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137

Bicycle Toxin Conjugates (BTCs) targeting EphA2 for the treatment of solid tumours: Discovery and selection of BT5528

Nectin-4-dependent immune cell stimulation and anti-tumor efficacy by BT7480, a Nectin-4/CD137 Bicycle® tumor-targeted immune cell agonist (TICA™)